Loading ...
Sorry, an error occurred while loading the content.

Re: [GIWorld-Hepatitis] A special day

Expand Messages
  • avansi7465
    Hi everybody: I just had to share this one with you. While we ve all moaned a groaned at one point or another about lack of knowledge, etc. from our various
    Message 1 of 1 , Jul 24, 2005
    • 0 Attachment
      Hi everybody:

      I just had to share this one with you. While we've all moaned a groaned at one point or another about lack of knowledge, etc. from our various health care professionals, I'd like to say a positive word. On Thursday, when I was having an especially bad day, I received a call from the head nurse, GI/Hepatology Dept. MCV. inquiring as to my treatment status and could MCV and their department be of help to me. Bear in mind that,to my knowledge, Healthnet Federal hasn't paid these last years bill. So............just thought I'd pass that one on as a small smile in all of this.

      Anne
      -----Original Message-----
      From: claudine intexas <claudineintexas@...>
      Sent: Jul 20, 2005 1:14 AM
      To: giworld-hepatitis@yahoogroups.com,
      Web Warriors <HepCWebWarriors@yahoogroups.com>
      Subject: [GIWorld-Hepatitis] [NATAP] Extrahepatic manifestations of HCV



      NATAP http://natap.org/
      _______________________________________________
      Extrahepatic manifestations of hepatitis C virus infection

      Sanjiv Chopra, MD
      Co-Editor-in-Chief - Gastroenterology/Hepatology
      Professor of Medicine
      Faculty Dean for Continuing Medical Education
      Harvard Medical School
      www.UpToDate.com

      INTRODUCTION - The hepatitis C virus (HCV) is a cause of both acute and chronic hepatitis. In addition, several extrahepatic diseases have been associated with chronic HCV infection, and in most cases appear to be directly related to the viral infection. These include [1-4]:

      * Hematologic diseases such as cryoglobulinemia and lymphoma
      * Autoimmune disorders such as thyroiditis and the presence of autoantibodies
      * Renal disease
      * Dermatologic conditions such as lichen planus and porphyria cutanea tarda

      In one series of 321 patients, at least one extrahepatic manifestation was observed in 38 percent (show table) [3]. These features of HCV infection will be reviewed here. The clinical manifestations of acute and chronic hepatitis due to HCV are discussed separately. (See "Clinical features and natural history of hepatitis C virus infection").

      HEMATOLOGIC DISORDERS - HCV infection is associated with a number of hematologic disorders including essential mixed cryoglobulinemia, monoclonal gammopathies (which may be associated with multiple myeloma), and lymphoma and less commonly monoclonal gammopathies.

      Essential mixed cryoglobulinemia - Mixed cryoglobulinemia is a lymphoproliferative disorder that can lead to deposition of circulating immune complexes in small to medium sized blood vessels. It often presents with the clinical triad of palpable purpura, arthralgias, and weakness, but can also involve the kidneys, peripheral nerves, and brain. (See "Clinical manifestations and diagnosis of mixed cryoglobulinemia").

      HCV infection appears to play an etiologic role in most patients with essential mixed cryoglobulinemia. As an example, three studies of 101 patients with this disorder found that 95 (95 percent) had one or more of the following signs of HCV infection [5-7]:

      * Circulating anti-HCV antibodies
      * The presence of polyclonal IgG anti-HCV antibodies within the cryoprecipitate
      * HCV RNA in the plasma and particularly the cryoprecipitate

      Another report prospectively evaluated the prevalence of cryoglobulins in 226 patients with chronic liver disease [8]. Of the 127 with chronic HCV infection, cryoglobulins were found in 69 (54 percent), frequently with anti-HCV antibody and HCV RNA concentrated in the cryoprecipitates (show figure 1). This incorporation of virus and antibody into the cryoprecipitate may sometimes reduce serum levels of anti-HCV and HCV RNA below detectable levels; this must be kept in mind when attempting to diagnose HCV infection in these patients. (See "Diagnostic approach to hepatitis C virus infection").

      The association of mixed cryoglobulinemia with HCV infection may be linked to the ability of the virus to bind to B lymphocytes via CD81 [9]. Binding lowers the activation threshold of these cells, thereby facilitating the production of autoantibodies.

      Further evidence for a causal relationship between HCV and essential mixed cryoglobulinemia is the demonstration of anti-HCV antibodies in the vessel walls of skin biopsies obtained from patients with mixed cryoglobulinemia and cutaneous vasculitis. In addition, cryoglobulin levels decrease and skin lesions and symptoms improve in association with a reduction in HCV virus when patients respond to treatment with interferon alfa (show figure 2) [8,10,11]. (See "Treatment of mixed cryoglobulinemia").

      Unfortunately, not all patients with HCV infection and cryoglobulinemia respond to interferon treatment. In addition, a reduction in cryoglobulin titers is not directly associated with a decrease in serum alanine aminotransferase (ALT) or HCV RNA.

      Treatment of patients with cryoglobulinemia due to HCV should be based upon the presence of cryoglobulinemia symptoms rather than the usual criteria used in patients with chronic hepatitis alone. (See "Treatment of chronic hepatitis C virus infection: Recommendations for adults"). Similarly, the response should be assessed by symptomatic improvement of cryoglobulinemia, a reduction in cryocrit, and an increase in serum complement levels. Complete responses may be more common in patients with low pretreatment levels of viremia and with high dose interferon regimens [12].

      Monoclonal gammopathies - Hepatitis C may be a risk factor for the development of monoclonal gammopathies. Prior to the development of tests for the hepatitis C virus, the prevalence of monoclonal gammopathies was noted to be increased in patients with chronic liver disease [13]. The ability to test for the hepatitis C virus permitted identification of patients who may be at greatest risk. A study of 239 HCV-positive patients compared to 98 HCV-negative controls (76 with chronic hepatitis B, 9 with alcoholic liver disease, and 13 with primary biliary cirrhosis) made the following observations [14]:

      * Monoclonal bands were detected in 11 percent (compared to 1 percent of a control, age-matched population)
      * The incidence peaked in the seventh decade
      * Nine of the 26 patients with a monoclonal band had either a smoldering myeloma or multiple myeloma (see "Diagnosis and differential diagnosis of multiple myeloma").
      * Monoclonal gammopathy was most often associated with HCV genotype 2a/c

      Lymphoma - Multiple reports have described an association between HCV infection and B-cell non-Hodgkins lymphoma (NHL). A meta-analysis that included 48 studies concluded that the prevalence of HCV in patients with B-cell NHL was 15 percent, much higher than the general population (around 1.5 percent) and in patients with other hematologic malignancies (2.9 percent) suggesting that HCV has an etiologic role [15].

      The strongest association with HCV infection is in the subset of patients with immunocytoma, a low-grade malignancy that has previously been associated with cryoglobulinemia [16,17]. HCV RNA has been isolated from the involved lymph nodes of some of these patients. Primary hepatic lymphoma has also been reported in association with HCV [18]. In addition, HCV has been described in gastric mucosa in association with MALT lymphomas (now called extranodal marginal zone B cell lymphoma of MALT type according to the REAL classification), raising the possibility that HCV, like Helicobacter pylori, may play an etiologic role in this low grade lymphoma [19-21]. (See "Association between Helicobacter pylori infection and gastrointestinal malignancy").

      It has also been suggested that HCV cryoglobulinemia could progress to a NHL. In one study, for example, 24 patients with chronic HCV infection and clinically active cryoglobulinemia were identified from a population of approximately 1500 patients with chronic HCV seen at a tertiary care referral center [22]. Sixteen of these 24 patients agreed to undergo molecular genetic testing and cellular flow analysis on bone marrow aspirates and biopsies. Nine (56 percent) had abnormal bone marrow morphology including seven (44 percent) with focal lymphoid aggregates that were suspicious for lymphoma, and two (13 percent) that were consistent with NHL.

      One of these two patients also had flow cytometric and molecular findings that were diagnostic of B-cell NHL. A trend toward increased clinical severity of cryoglobulinemia was noted among the nine patients who had bone marrow samples suspicious for lymphoma. No patients had systemic symptoms associated with lymphoma or were treated with chemotherapy. However, the distinction between lymphoma and lymphoid infiltrates on bone marrow specimens can be difficult, which was reflected by the observation that only one patient (6 percent) had molecular and flow-cytometric evidence supporting a diagnosis of NHL [22]. A higher proportion (30 percent) of patients with HCV, cryoglobulinemia and bone marrow specimens suspicious for NHL were found to have flow cytometric findings consistent with NHL in another report [6].

      These data support the hypothesis that cryoglobulinemia may arise from chronic stimulation of the immune system by HCV, which may predispose to a lymphoproliferative disorder. (See "Clinical manifestations and diagnosis of mixed cryoglobulinemia"). The subsequent steps leading to the development of a lymphoproliferative disorder are uncertain. As mentioned above, patients with HCV are more likely than controls to have t(14;18) translocation with overexpression of the antiapoptotic bcl-2 proto-oncogene [23] and bcl-2 rearrangements [24-26], suggesting that bcl-2 may be a contributing factor to lymphoma development [23]. Some HCV-associated lymphomas produce soluble immunoglobulins directed against the E2 protein (an HCV envelope glycoprotein) [27]. This observation supports the hypothesis that some HCV-associated lymphomas originate from B cells that were initially activated by the HCV-E2 protein.

      The population attributable risk of HCV to lymphoma (ie, the proportion of the population whose lymphoma is caused by HCV) is probably low, and an association with HCV and lymphoma has not been detected in all reports [28]. Nevertheless, the development of unexplained anemia or lymphadenopathy in a patient with HCV and clinically active cryoglobulinemia should raise concern about an underlying lymphoproliferative disorder [6]. Whether treatment of the underlying HCV infection could be effective in such patients is uncertain [26]. Regression of splenic lymphoma was described in association with HCV treatment in a case series [29]. (See "Clinical and pathologic features of the marginal zone lymphomas", section on Association with HCV infection).

      DIABETES MELLITUS - HCV infection has been linked to diabetes mellitus in several epidemiologic studies [30-38]. An illustrative study of1117 patients with chronic viral hepatitis found that diabetes was present in significantly more patients with hepatitis C compared to hepatitis B virus (HBV) infection (21 versus 12 percent) [34]. HCV genotype 2a was overrepresented among the diabetic patients. In a separate case-control trial included in the same report, the prevalence of HCV infection was significantly higher among patients with diabetes mellitus compared to controls (4.2 versus 1.6 percent). A transgenic animal model suggested that the HCV core gene may be directly involved in the development of insulin resistance [39].

      Risk factors for the development of diabetes mellitus in HCV infected patients included older age, obesity, severe liver fibrosis, and a family history of diabetes mellitus [40]. Patients undergoing liver transplantation for HCV also appear to be at increased risk, compared to other liver diseases, for developing diabetes mellitus following transplantation [41].

      The cause of these associations is unknown, but their magnitude may be overestimated based upon the retrospective nature of the above reports and the following factors [42]:

      * Patients with diabetes have more parenteral exposures than the general population, placing them at increased risk for transmission of viruses.

      * HCV infection becomes chronic more often than HBV infection.

      * Not all studies are controlled for the presence of cirrhosis, which may be associated with impaired glucose tolerance.

      HCV has also been linked to insulin resistance without overt diabetes. It has been suggested that the associated insulin resistance may contribute to fibrosis progression [43].

      AUTOIMMUNE DISORDERS - A number of autoimmune disorders have been associated with HCV infection, including autoantibody formation, thyroid disease, sialoadenitis, and autoimmune idiopathic thrombocytopenic purpura.

      Autoantibodies - Autoantibodies are common in patients with chronic HCV infection; antinuclear antibodies, antibodies directed against the Fc portion of IgG (rheumatoid factor), anticardiolipin antibodies, smooth muscle antibodies, or antithyroid antibodies are detected in 40 to 65 percent of patients [3,44,45]. These antibodies are typically present in low titer, and do not appear to influence the presentation or course of infection; they are not usually associated with extrahepatic disease.

      However, their presence may result in diagnostic difficulties; as an example, the HCV-infected patient with arthralgias, arthritis, and rheumatoid factor positivity may be initially misdiagnosed as having rheumatoid arthritis. In this setting, testing for other RA-associated autoantibodies infrequently observed in patients with HCV infection, such as anti-citrullinated peptide (eg, anti-cyclic citrullinated peptid or CCP) antibodies, may be helpful diagnostically [46]. (See "Origin and utility of measurement of rheumatoid factors").

      Autoantibodies may first become detectable or can increase in titer during interferon treatment. (See "Principles of interferon therapy in liver disease and the induction of autoimmunity"). However, since their presence does not affect the disease course or the response to treatment, autoantibody formation is not a reason to stop therapy.

      Antibodies to actin and to liver/kidney microsomes (anti-LKM-1) are characteristic of types 1 and 2 autoimmune hepatitis, respectively. (See "Clinical manifestations and diagnosis of autoimmune hepatitis"). These antibodies have been detected in some patients with chronic HCV infection, particularly in Europe [47-49].

      Most patients with hepatitis C and anti-LKM-1 antibodies, as well as other types of non-organ-specific autoantibodies, appear to benefit from interferon to the same extent as patients with chronic hepatitis C without such antibodies. However, such patients need meticulous monitoring during interferon treatment, since flares of aminotransferases without subsequent clearance of HCV RNA have been observed [50,51]. This observation suggests that these patients may behave as if they had autoimmune hepatitis. In support of this hypothesis is the finding that when patients with chronic hepatitis C with or without anti-LKM-1 antibodies were compared, the viral load was lower in the patients with anti-LKM-1 antibodies even though both groups had disease of similar severity [52]. Furthermore, some of these patients have responded to prednisone and azathioprine, directed against presumed autoimmune hepatitis [53,54]. One possible method of determining whether the hepatitis is primarily due to
      HCV or autoimmune hepatitis is that the anti-LKM-1 antibodies in patients with HCV are directed at different epitopes of cytochrome P450 2D6 (CYP2D6, the target antigen) from that seen with autoimmune hepatitis [55,56].

      Thyroid disease - Thyroid disorders are common in patients with chronic HCV, particularly women [57,58]. One of the largest studies included 630 consecutive patients with HCV (without cirrhosis) who were compared with 389 subjects from an iodine-deficient area, another control group of 268 persons from an area of iodine sufficiency, and 86 patients with chronic hepatitis B [58]. Mean TSH levels were significantly higher and free T3 and T4 levels significantly lower in patients with HCV than in all other groups. Patients with HCV were more likely than controls to have hypothyroidism (13 versus 3 to 5 percent ), anti-thyroglobulin antibodies (17 versus 9 to 10 percent), and anti-thyroidperoxidase antibodies (21 versus 10 to 13 percent). Another report suggested that thyroid abnormalities were seen predominantly in women [57]. (See "Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)").

      Overall, antithyroid antibodies are present in 5 to 17 percent of patients with HCV infection, and thyroid disease, primarily hypothyroidism, occurs in 2 to 13 percent of patients [57,58]. The highest prevalence of both thyroid antibodies and thyroid disease is found in older women. However, whether or not the prevalence is higher than in age- and sex-matched controls is controversial [59,60].

      A separate issue is the development of thyroid disease in patients with HCV infection who are treated with interferon alfa. Approximately 1 to 5 percent of such patients develop painless thyroiditis. Other thyroid abnormalities can also occur, including Graves' disease and permanent hypothyroidism, or increased serum antithyroid antibody concentrations without thyroid dysfunction [59-62]. The changes in thyroid function usually appear after three months of therapy, but can occur as long as interferon alfa is given.

      The risk of any form of thyroid disease is greater in those patients who have increased serum antithyroid antibody concentrations before the initiation of therapy, a finding which suggests that interferon alfa in some way exacerbates underlying thyroid autoimmune disease. (See "Principles of interferon therapy in liver disease and the induction of autoimmunity", section on Thyroid disease). The presence of antithyroid peroxidase antibodies appears to be the most significant risk factor for the development of thyroid dysfunction during interferon therapy [62]. Other risk factors may include female gender, older age, and the presence of other autoantibodies [60]. Women with chronic hepatitis C and high antithyroid peroxidase antibody titers are at particular risk.

      Thyroid dysfunction may resolve following the discontinuation of interferon treatment.

      In summary, all patients receiving interferon alfa should be monitored for thyroid disease, particularly women and patients with preexisting antithyroid antibodies. Interferon therapy usually can be continued while hypothyroidism is being treated. On the other hand, we have usually stopped interferon in patients who develop clinically apparent hyperthyroidism.

      Sialoadenitis - A lymphocytic sialadenitis suggestive of Sjögren's syndrome has been described in patients with chronic HCV infection [63,64]. A study of 137 patients with Sjögren's syndrome and HCV suggested that the clinical and immunologic features were indistinguishable from Sjögren's syndrome in patients without HCV [64]. (See "Classification and diagnosis of Sjögren's syndrome").

      Autoimmune idiopathic thrombocytopenic purpura - Anti-HCV antibodies occur in 10 to 19 percent of patients with autoimmune idiopathic thrombocytopenic purpura (ITP). However, the diagnosis of autoimmune ITP usually predates HCV infection, suggesting that the latter results from the transfusion of blood products [65]. On the other hand, ITP has been reported to develop during interferon therapy for HCV. Thus, the relationship between autoimmune ITP and HCV remains to be clarified.

      Myasthenia gravis - An association between myasthenia gravis (MG) and hepatitis C virus infection has been suggested in case reports [66,67], although a causal association has not been clearly established [68]. MG has also been described in association with administration of interferon, possibly because of exacerbation of preexisting subclinical disease [69,70].

      Sarcoidosis - Sarcoidosis has been described in association with HCV, mostly in the setting of antiviral therapy. (See "Administration of combined interferon alfa-2b and ribavirin in the treatment of hepatitis C virus infection").

      OCULAR DISEASE - HCV infection has been associated with a variety ophthalmologic disorders including corneal ulcers (Mooren's ulcer), uveitis, and scleritis [71-73], and sicca syndrome in patients with HCV-related Sjogren's syndrome [74]. In addition, ophthalmologic disorders (retinal hemorrhages, cotton wool spots, and rarely retinal artery or vein obstruction) can occur during interferon therapy. (See "Administration of combined interferon alfa-2b and ribavirin in the treatment of hepatitis C virus infection").

      RENAL DISEASE - Glomerular disease may occur in patients with chronic HCV infection. The most common patterns are membranoproliferative glomerulonephritis (usually associated with essential mixed cryoglobulinemia) and, less frequently, membranous nephropathy [75]. Several series have reported that anti-HCV antibodies are nearly universal in patients with both membranoproliferative disease and cryoglobulinemia; the pathogenesis appears to relate to deposition of immune complexes containing anti-HCV and HCV RNA in the glomeruli. (See "Renal disease with hepatitis C virus infection").

      Interferon alfa is indicated in patients with mixed cryoglobulinemia and membranoproliferative glomerulonephritis. A number of studies have reported a beneficial response to antiviral therapy in this setting, and the reduction in proteinuria correlates with a fall in HCV RNA [5,75,76]. However, long-term responses to interferon are unusual; maintenance treatment may be required, and renal function is often not improved by treatment.

      DERMATOLOGIC DISEASE - A variety of dermatologic diseases may be associated with HCV infection [77].

      Porphyria cutanea tarda - Porphyria cutanea tarda (PCT) is a skin disease caused by a reduction of hepatic uroporphyrinogen decarboxylase activity that is characterized by photosensitivity, skin fragility, bruising, and vesicles or bullae that can become hemorrhagic. There is a strong association between the sporadic form of PCT and HCV infection. The precise mechanism by which HCV infection might cause or act as a trigger for PCT in predisposed subjects is not known. (See "Porphyria cutanea tarda and hepatitis C virus infection").

      All patients with PCT should be screened for HCV infection, as well as other potential precipitating factors. Treatment with interferon alfa should be considered in HCV-infected patients.

      Leukocytoclastic vasculitis - A leukocytoclastic vasculitis may occur in conjunction with essential mixed cryoglobulinemia, presenting clinically with palpable purpura and petechiae that usually involve the lower extremities (show picture 1). (See "Clinical manifestations and diagnosis of mixed cryoglobulinemia"). Skin biopsy demonstrates cutaneous vasculitis with dermal blood vessel destruction associated with neutrophilic infiltration in and around the vessel wall (show histology 1A-1B).

      Other tissues, particularly the lower extremity peripheral nerves, may show similar vasculitic changes involving the vasa nervorum [78]. This may be manifested clinically as a peripheral neuropathy which, as in other forms of vasculitis, is typically asymmetric (also called a mononeuritis multiplex). (See "Vasculitic peripheral neuropathy").

      Lichen planus - Lichen planus (LP) is characterized by flat-topped, violaceous, pruritic papules with a generalized distribution. It can also involve mucus membranes, hair, and nails. LP may be mediated through the cellular immune response, although the actual precipitating mechanism is not known [79]. Skin biopsy demonstrates a dense lymphocytic infiltration in the upper dermis.

      LP can be seen in patients with a variety of liver diseases, particularly advanced liver disease; anti-HCV antibodies are present in 10 to 40 percent of these patients but a cause-and-effect relation is uncertain [1]. There are also reports of the development or exacerbation of lichen planus during interferon treatment for chronic HCV; the lesions improved when interferon was stopped [80].

      MUSCULOSKELETAL - Hepatitis C-associated osteosclerosis is a rare disorder characterized by a marked increase in bone mass during adult life. While most cases have been reported in patients with a history of intravenous drug abuse, it has also been seen with hepatitis C after blood transfusion [81]. Periosteal, endosteal and trabecular bone thickening occurs throughout the skeleton with the exception of the cranium. During active disease, forearm and leg pain are common, bone remodeling (turnover) is high, and bone mineral density is two- to three-fold higher than age-matched norms. The increased remodeling may respond to bisphosphonates or calcitonin, but spontaneous remission has also been described. Abnormalities in insulin-like growth factors (IGF-1 and IGF-II) or their binding proteins may contribute to the increase in bone formation in this disorder [82].

      Arthritis is noted in 2 to 20 percent of HCV patients. The arthritis is an evanescent rheumatoid-like picture in two-thirds of the cases and an oligoarthritis in the rest. (See "Specific viruses that cause arthritis").

      MYOCARDITIS AND CARDIOMYOPATHY - HCV has been associated with myocarditis and cardiomyopathy in reports from Japan. The pathogenesis is unclear. (See "Etiology and pathogenesis of myocarditis").

      NEUROCOGNITIVE DYSFUNCTION - Several studies have suggested that HCV infection may be associated with neurocognitive dysfunction even without advanced liver disease. The potential mechanisms are unclear. (See "Clinical manifestations and diagnosis of hepatic encephalopathy").

      Use of UpToDate is subject to the Subscription and License Agreement.
      REFERENCES
      1. Gumber, SC, Chopra, S. Hepatitis C: A multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 126:615.
      2. Pawlotsky, JM, Ben Yahia, M, Andre, C, et al. Immunologic disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994; 19:841.
      3. Cacoub, P, Renou, C, Rosenthal, E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Medicine (Baltimore) 2000; 79:47.
      4. El-Serag, HB, Hampel, H, Yeh, C, Rabeneck, L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36:1439.
      5. Agnello, V, Chung, RT, Kaplan, LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490.
      6. Pozzato, G, Mazzaro, C, Crovatto, M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84:3047.
      7. Misiani, R, Bellavita, P, Fenili, D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573.
      8. Lunel, F, Musset, L, Cacoub, P, et al. Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291.
      9. Pileri, P, Uematsu, Y, Campagnoli, S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938.
      10. Misiani, R, Bellavita, P, Fenili, D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751.
      11. Ferri, C, Marzo, E, Longomabardo, G, et al. Interferon-alpha in mixed cryoglobulinemia patients: A randomized crossover-controlled trial. Blood 1993; 81:1132.
      12. Casato, M, Agnello, V, Pacillo, LP, et al. Predictors of long term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90:3865.
      13. Heer, M, Joller-Jemelka, H, Fontana, A, et al. Monoclonal gammopathy in chronic active hepatitis. Liver 1984; 4:255.
      14. Andreone, P, Zignegno, AL, Cursaro, C, et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998; 129:294.
      15. Gisbert, JP, Garca-Buey, L, Pajares, JM, Moreno-Otero, R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: Systematic review and meta-analysis. Gastroenterology 2003; 125:1723.
      16. Silvestri, F, Pipan, C, Barillari, G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996; 87:4296.
      17. Monti, G, Pioltelli, P, Saccardo, F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005; 165:101.
      18. Bronowicki, JP, Bineau, C, Feugier, P, Hermine, O. Primary lymphoma of the liver: Clinical-pathological features and relationship with HCV infection in French patients. Hepatology 2003; 37:781.
      19. Luppi, M, Longo, G, Ferrari, MG, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 1996; 94:373.
      20. De Vita, S, De Re, V, Sansonno, D, et al. Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and chronic gastritis. Hepatology 2000; 31:182.
      21. Tursi, A, Brandimante, G, Chiarelli, F, et al. Detection of HCV RNA in gastric mucosa-associated lymphoid tissue by in situ hybridization: Evidence of a new extrahepatic localization of HCV with increased risk of gastric malt lymphoma. Am J Gastroenterol 2002; 97:1802.
      22. Rasul, I, Sheperd, FA, Kamel-Reid, S, et al. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 1999; 29:543.
      23. Zignego, AL, Giannelli, F, Marrocchi, ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000; 31:474.
      24. Kitay-Cohen, Y, Amiel, A, Hilzenrat, N, et al. Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood 2000; 96:2910.
      25. Zuckerman, E, Zuckerman, T, Sahar, D, et al. bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 2001; 112:364.
      26. Zignego, AL, Ferri, C, Giannelli, F, et al. Prevalence of bcl-2 Rearrangement in Patients with Hepatitis C Virus-Related Mixed Cryoglobulinemia with or without B-Cell Lymphomas. Ann Intern Med 2002; 137:571.
      27. Quinn, ER, Chan, CH, Hadlock, KG, et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98:3745.
      28. Collier, JD, Zanke, B, Moore, M, et al. No association between hepatitis C and B-cell lymphoma. Hepatology 1999; 29:1259.
      29. Hermine, O, Lefrere, F, Bronowicki, JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89.
      30. Allison, ME, Wreghitt, T, Palmer, CR, Alexander, GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21:1135.
      31. Fraser, GM, Harman, I, Meller, N, et al. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B virus infection. Isr J Med Sci 1996; 32:526.
      32. Grimbert, S, Valensi, P, Levy-Marchal, C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case control study. Gastroenterol Clin Biol 1996; 20:544.
      33. Ozyilkan, E, Arslan, M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection [letter]. Am J Gastroenterol 1996; 91:1480.
      34. Mason, AL, Lau, JY, Hoang, N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29:328.
      35. Caronia, S, Taylor, K, Pagliaro, L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30:1059.
      36. Mehta, SH, Brancati, FL, Sulkowski, MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133:592.
      37. Mehta, SH, Brancati, FL, Strathdee, SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38:50.
      38. Zein, Co, Levy, C, Basu, A, Zein, NN. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005; 100:48.
      39. Shintani, Y, Fujie, H, Miyoshi, H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840.
      40. Petit, JM, Bour, JB, Galland-Jos, C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35:279.
      41. Bigam, DL, Pennington, JJ, Carpentier, A, et al. Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. Hepatology 2000; 32:87.
      42. Hadziyannis, S, Karamanos, B. Diabetes mellitus and chronic hepatitis C virus infection (editorial). Hepatology 1999; 29:604.
      43. Hui, JM, Sud, A, Farrell, GC, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003; 125:1695.
      44. Clifford, BD, Donahue, D, Smith, L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613.
      45. Cacoub, P, Musset, L, Amoura, Z, et al. Anticardiolipin, anti-beta2-Glycoprotein I, and antinucleosome antibodies in hepatitis C virus infection and mixed cryoglobulinemia. J Rheumatol 1997; 24:2139.
      46. Lienesch, D, Morris, Metzger, A, et al. Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepaptis C infection. J Rheumatol 2005; 32:489.
      47. Zauli, D, Ghetti, S, Grassi, A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25:1105.
      48. Bianchi, FB. Autoimmune hepatitis: The lesson of the discovery of hepatitis C virus. J Hepatol 1993; 18:273.
      49. Reddy, KR, Krawitt, EL, Homberg, JC, et al. Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat 1995; 2:175.
      50. Muratori, L, Lenzi, M, Cataleta, M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21:199.
      51. Gschwantler, M, Schrutka-Kolbl, C, Weiss, W. Acute exacerbation of antiliver cytosol antibody-positive autoimmune chronic hepatitis by alpha-interferon. Am J Gastroenterol 1995; 90:2239.
      52. Giostra, F, Manzin, A, Lenzi, M, et al. Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. J Hepatol 1996; 25:433.
      53. Bellary, S, Schiano, T, Hartman, G, et al. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: Favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123:32.
      54. Bortolotti, F, Vajro, P, Balli, F, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25:614.
      55. Yamamoto, AM, Cresteil, D, Homberg, JC, et al. Characterization of anti-liver kidney microsome antibody (anti-LKM-1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993; 104:1762.
      56. Muratori, L, Lenzi, M, Ma, Y, et al. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995; 37:406.
      57. Tran, A, Quaranta, JF, Benzaken, S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18:253.
      58. Antonelli, A, Ferri, C, Pampana, A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117:10.
      59. Roti, E, Minelli, R, Giuberti, T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101:482.
      60. Marazuela, M, Garcia-Buey, L, Gonzalez-Fernandez, B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol 1996; 44:635.
      61. Nagayama, Y, Ohta, K, Tsuruta, M, et al. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: Our studies and review of the literature. Endocr J 1994; 41:565.
      62. Deutsch, M, Dourakis, S, Manesis, EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26:206.
      63. Haddad, J, Deny, P, Munz-Gotheil, et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339:321.
      64. Ramos-Casals, M, Loustaud-Ratti, V, De Vita, S, Zeher, M. Sjogren Syndrome Associated With Hepatitis C Virus: A Multicenter Analysis of 137 Cases. Medicine (Baltimore) 2005; 84:81.
      65. Pawlotsky, JM, Bouvier, M, Fromont, P, et al. Hepatitis C virus infection and autoimmune thrombocytopenia purpura. J Hepatol 1995; 23:635.
      66. Eddy, S, Wim, R, Peter, VE, et al. Myasthenia gravis: Another autoimmune disease associated with hepatitis C virus infection. Dig Dis Sci 1999; 44:186.
      67. Reading, PJ, Newman, PK. Untreated hepatitis C may provoke myasthenia gravis [letter]. J Neurol Neurosurg Psychiatry 1998; 64:820.
      68. Halfon, P, Levy, M, San Marco, M, et al. Myasthenia gravis and hepatitis C virus infection. J Viral Hepat 1996; 3:329.
      69. Harada, H, Tamaoka, A, Kohno, Y, et al. Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C. J Neurol Sci 1999; 165:182.
      70. Gurtubay, IG, Morales, G, Arechaga, O, Gallego, J. Development of myasthenia gravis after interferon alpha therapy. Electromyogr Clin Neurophysiol 1999; 39:75.
      71. Wilson, SE, Lee, WM, Murakami, C, et al. Mooren's corneal ulcers and hepatitis C virus infection (letter). N Engl J Med 1993; 329:62.
      72. Ali, Y, Ghafouri, M, Weitzman, M, et al. Refractory scleritis in a patient with cryoglobulinemia and hepatitis C (letter). J Clin Rheumatol 1999; 5:371.
      73. Moder, KG, Poterucha, JJ, Mahr, MA. Scleritis associated with viral hepatitis C: Report of a case. J Clin Rheumatol 2000.
      74. Ramos-Casals, M, Loustaud-Ratti, V, De Vita, S, et al. Sjogren Syndrome Associated With Hepatitis C Virus: A Multicenter Analysis of 137 Cases. Medicine (Baltimore) 2005; 84:81.
      75. Johnson, RJ, Gretch, DR, Couser, WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46:1700.
      76. Johnson, RJ, Gretch, DR, Yamabe, H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465.
      77. Daoud, MS, Gibson, LE, Daoud, S, el-Azhary, RA. Chronic hepatitis C and skin diseases: A review. Mayo Clin Proc 1995; 70:559.
      78. David, WS, Peine, C, Schlesinger, P, Smith, SA. Nonsystemic vasculitic mononeuropathy multiplex cryoglobulinemia, and hepatitis C. Muscle Nerve 1996; 19:1596.
      79. Pilli, M, Penna, A, Zerbini, A, Vescovi, P. Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology 2002; 36:1446.
      80. Protzer, U, Ochsendorf, FR, Leopolder-Ochsendorf, A, Holtermuller, KH. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104:903.
      81. Shaker, JL, Moore, BP, Whyte, MP. Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 1999; 84:384.
      82. Khosla, S, Hassoun, AA, Baker, BK, et al. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 1998; 101:2165.











      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      ----------

      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      [Non-text portions of this message have been removed]



      Welcome to GIHepWorld

      Post message: GIWorld-Hepatitis@yahoogroups.com
      Subscribe: GIWorld-Hepatitis-subscribe@yahoogroups.com
      Unsubscribe: GIWorld-Hepatitis-unsubscribe@yahoogroups.com
      List owner: GIWorld-Hepatitis-owner@yahoogroups.com
      URL to this page: http://groups.yahoo.com/group/GIWorld-Hepatitis

      Yahoo! Groups Links
    Your message has been successfully submitted and would be delivered to recipients shortly.